✦ LIBER ✦

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

✍ Scribed by John P. Caloyeras; Bin Zhang; Cheng Wang; Marianne Eriksson; Sten Fredrikson; Karola Beckmann; Volker Knappertz; Christoph Pohl; Hans-Peter Hartung; Dhvani Shah; Jeffrey D. Miller; Rupert Sandbrink; Vivian Lanius; Kathleen Gondek; Mason W. Russell

Book ID: 113544629
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 882 KB
Volume: 34
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2012.03.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND15 COST-UTILITY OF INTERFERON BETA-1B

PND15 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS

✍ JP Caloyeras; C Wang; L Bauer; WC Lee; V Lanius; K Gondek 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PND26 COST-UTILITY OF INTERFERON BETA-1B

PND26 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN

✍ T Arbizu; C Piñol; V Casado 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Long-term effect of early treatment with

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

✍ Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 239 KB

Effect of early versus delayed interfero

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

✍ Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB

Human herpesvirus 6 and effectiveness of

Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients

✍ M. Garcia-Montojo; V. De Las Heras; M. Dominguez-Mozo; M. Bartolome; M. A. Garci 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

ND4 COST-UTILITY OF INTERFERON BETA-1B I

ND4 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA

✍ JP Caloyeras; B Harrow; C Wang; K Beckmann; V Knappertz; C Pohl; JD Miller; MW R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB